Clinical Trials Logo
  1. Home
  2. Psoriatic Arthritis
  3. NCT01891903
  4. Details
NCT01891903 Clinical Trial

to Translate and Validate the TOPAS TORONTO PSORIATIC SCREENING QUESTIONNAIRE)Into Spanish

Psoriatic Arthritis Clinical Trial

— spanishTopas  

Official title:
TO TRANSLATE AND VALIDATE THE ToPAS (TORONTO PSORIATIC SCREENING QUESTIONNAIRE) FOR THE SCREENING OF PSORIATHIC ARTHRITIS PATIENTS IN DERMATOLOGY CLINICS

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT01891903
Other study ID # TOPAS52424166
Secondary ID
Status Recruiting
Phase N/A
First received June 18, 2013
Last updated June 28, 2013
Start date May 2013
Est. completion date September 2013

Study information
Verified date June 2013
Source Reumatologia Integral LTDA
Contact n/a
Is FDA regulated No
Health authority Colombia: Ethics Committee
Study type Observational [Patient Registry]

Clinical Trial Summary

TO TRANSALETE AND VALIDATE DE TORONTO PSORIATIC ARTHRITIS SECREENING QUESTIONAIRE INTO SPANISH

Description:

THIS IS PART OF THE COLOMBIAN REGISTRY OF PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS

Recruitment information / eligibility
Status Recruiting
Enrollment 60
Est. completion date September 2013
Est. primary completion date August 2013
Accepts healthy volunteers No
Gender Both
Age group 16 Years and older
Eligibility Inclusion Criteria:

- ADULT WITH PSORIASIS IN THE DERMATOLOGY CLINIC

Exclusion Criteria:

- ADULT WITH OTHER AUTOIMMUNE DISEASE

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Colombia Hospital Universitario Clinica San Rafael Bogota Cundinamarca

Sponsors (1)
Lead Sponsor Collaborator
Reumatologia Integral LTDA

Country where clinical trial is conducted

Colombia, 

Outcome
Type Measure Description Time frame Safety issue
Primary The Kuder Richardson Coefficient of reliability (K-R 20) 4 MONTHS No
See also
  Status Clinical Trial Phase
Completed NCT04152759 - Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects Phase 1
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT01925768 - Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis Phase 3
Completed NCT01892436 - Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis Phase 3
Completed NCT01212770 - PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Phase 3
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT01212757 - PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis Phase 3
Completed NCT03953378 - CD73+ Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis
Recruiting NCT02572700 - Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis
Completed NCT02556034 - Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02188654 - Metformin in Psoriatic Arthritis N/A
Completed NCT02164214 - Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)? Phase 3
Completed NCT01392326 - Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) Phase 3
Completed NCT01083693 - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs N/A
Not yet recruiting NCT00517101 - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy N/A
Completed NCT00133315 - TNFalfa Blocking Treatment of Spondylarthropathies Phase 4
Completed NCT00659412 - A Placebo-controlled Study With an Extension Examining the Safety and Efficacy of Alefacept in Psoriatic Arthritis Phase 2
Completed NCT00946686 - To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting Conditions Phase 1
Not yet recruiting NCT06059430 - Cohort Project of Patients With Inflammatory Rheumatism